TargetMol Chemicals Inc.

Firmenname:TargetMol Chemicals Inc.
Telefon:781-+1-781-999-5354
E-Mail:marketing@targetmol.com
Nationalität:United States
URL: https://www.targetmol.com/
Produkte insgesamt:19892

Produktkatalog

GDC-08341133432-49-1C33H36N6O3S
Taurocholic acid sodium salt hydrate;Taurocholic Acid sodium hydrate;Sodium taurocholate hydrate345909-26-4C26H46NNaO8S
GDP-?α-D-?mannose disodium148296-46-2C16H23N5Na2O16P2
GDP366501698-03-9C20H17N5OS
Pictilisib dimethanesulfonate;GDC-0941 2 MeSO3H salt;GDC-0941 dimethanesulfonate957054-33-0C24H30N7O6S3
GDC-0927;SRN-9271642297-01-5C28H28FNO4
Genz-123346943344-58-9C52H82N4O14
Gemcabene calcium;PD-72953 calcium209789-08-2C16H32CaO5
Salbutamol;AH-3365;AlbuterolSalbutamol18559-94-9C13H21NO3
Gefitinib-d8;ZD1839 D8;Gefitinib D8857091-32-8C22H24ClFN4O3
Gemfibrozil 1-O-β-glucuronide91683-38-4C21H30O9
Gemcabene;PD-72953183293-82-5C16H30O5
Gemilukast;ONO-69501232861-58-3C36H37F2NO5
Gefitinib N-oxide847949-51-3C22H24ClFN4O4
Ginsenoside Ra390985-77-6C59H100O27
GKA50851884-87-2C26H28N2O6
Gepotidacin;GSK21409441075236-89-3C24H28N6O3
GGTI-2418501010-06-6C23H31N5O4
GFB-84382304549-73-1C16H14ClF3N4O2
GLPG0492 (R enantiomer);GLPG0492 R enantiomer1215085-93-0C19H14F3N3O3
GET73;GET 73;Gamma hydroxybutyric acid analogue202402-01-5C13H16F3NO2
GLPG04921215085-92-9C19H14F3N3O3
Doxycycline hydrochloride;Hyclate;Vibramycin;Doxylin2-Naphthacencarboxamid, 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, Monohydrochlorid, [4S-(4α,4aα,5α,5aα,6α,12aα)]-10592-13-9C22H25ClN2O8
Gln-AMS209543-57-7C15H22N8O8S
Gisadenafil besylate;UK 369003-26334827-98-4C29H39N7O8S2
GGTI298180977-44-0C27H33N3O3S
Germacrene D23986-74-5C15H24
Giredestrant;GDC-95451953133-47-5C27H31F5N4O
GENZ-882706;RA035468492070864-35-4C26H25N5O3
GF 15888042-13-5C23H21ClO6
GLUT4 activator 12253733-37-6C23H21FN4O3S
GLP-262133017-36-2C19H17F2N3O3
Glucagon receptor antagonists-3202917-17-7C22H30FNO2
Glyoxalase I inhibitor free base174568-92-4C21H29BrN4O8S
Antibacterial compound 2170104-58-2C22H30FN5O6
Glucokinase activator 11328987-85-4C27H20F2N2O7S2
TT-OAD2 free base1246826-07-2C50H47Cl2N3O6
Glycosidase-IN-2476310-39-1C13H23NO5
Glucagon receptor antagonists-1503559-84-0C29H34FNO2
Glucocorticoid receptor agonist1245526-82-2C20H20F4N2O2
Gly-β-MCA66225-78-3C26H43NO6
Glutaminyl Cyclase Inhibitor 32092921-50-9C24H32N6O2S
GLP-1 receptor agonist 12212020-52-3C48H48F2N10O5
GLP-1 receptor agonist 41187061-62-6C51H44Cl2N4O6
Glucagon receptor antagonists-2202917-18-8C22H30FNO2
Glutaminyl Cyclase Inhibitor 12110449-60-8C21H24FN3O2
GLPG12051445847-37-9C22H22N2O4
Glycolic acid oxidase inhibitor 177529-42-1C16H10BrNO3
O6BTG-octylglucoside;Glucose-conjugated MGMT inhibitor382607-78-5C24H34BrN5O7S
Glyco-Obeticholic acid863239-60-5C28H47NO5
Glutaminyl Cyclase Inhibitor 42376329-36-9C22H33N5O3
Glyoxalase I inhibitor221174-33-0C21H30BrClN4O8S
Carbenicillin disodium;Sodium carbenicillin;BRL-2064Dinatrium-[2S-(2α,5α,6β)]-6-(carboxylatophenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-carboxylat4800-94-6C17H19N2NaO6S
Glutaminase-IN-1;CB839 derivative2247127-79-1C26H24F3N7O3Se
IPN60090;GLS1-IN-11853164-83-6C24H27F3N8O3
Glucagon receptor antagonists-52200274-63-9C30H29ClF3N3O3
Clindamycin phosphate;Clindamycin 2-phosphate;U-28508;Clindamycin 2-dihydrogen phosphate;NSC 618653Methyl-7-chlor-6,7,8-tridesoxy-6-(((1-methyl-4-propyl-2-pyrrolidi-nyl)carbonyl)amino)-1-thio-L-threo-alpha-D-galacto-octopyrano-sid-2-(dihydrogenphosphat),(2S-trans)-24729-96-2C18H34ClN2O8PS
Glutaminyl Cyclase Inhibitor 21884546-29-5C19H20FN3
GLP-1 receptor agonist 22230197-64-3C30H31ClFN5O4
Fenbendazole;Fenbendazol;Phenbendasol;PanacurFenbendazol43210-67-9C15H13N3O2S
GLP-1 receptor agonist 32230200-09-4C31H30FN5O4
Glycosidase-IN-1170376-12-2C13H23NO5
GSK-3 inhibitor 1603272-51-1C22H17ClFN5O2
Golotimod;SCV 07;Gamma-D-glutamyl-L-tryptophan229305-39-9C16H19N3O5
GlyRS-IN-1112921-11-6C12H17N7O7S
GPR120 Agonist 11628448-77-0C20H12ClF6NO3S
GSK-3β inhibitor 1187325-53-7C14H10N2O
Lenacapavir;GS-62072189684-44-2C39H32ClF10N7O5S2
GPR120 modulator 11050506-75-6C19H16ClNO4S
GPR40 Activator 21312787-30-6C28H29NO6S2
GPR40/FFAR1 modulator 1874755-26-7C21H19N5O3
GPR120 modulator 21050506-87-0C20H18ClNO3S
GNE-85051620573-48-9C21H24F3N5O
GPI-1046186452-09-5C20H28N2O4
Gosogliptin;PF-00734200;PF-734200869490-23-3C17H24F2N6O
GNF179 (Metabolite);GNF179 Metabolite1310455-86-7C14H16FN3
GNF-62311243245-18-2C24H25FN6O2
GNE 2201199590-75-4C25H26N8
GNF3621003019-41-7C22H21F3N6
Lidocaine hydrochloride;Xyloneural;Lidocaine HCL;Lidothesin;Lignocaine hydrochlorideLidocainhydrochlorid73-78-9C14H23ClN2O
GPR40 Activator 11309435-60-6C31H31NO3S
GRL06171093070-16-6C20H20N2O
GNA0021385035-79-9C42H55NO8
Lidocaine Hydrochloride hydrate6108-05-0C14H25ClN2O2
GPR84 antagonist 81445846-30-9C23H23N3O5
GNF48772041073-22-5C25H27FN6O4
GlyT1 Inhibitor 11820934-93-7C22H21N5O2
GPR4 antagonist 11197879-16-5C27H37N5
Nifedipine;Procardia XL;Procardia;BAY-a-1040;Adalat1,4-Dihydro-2,6-dimethyl-4-(2-ni-trophenyl)-3,5-pyridindicarbon-säure-dimethylester21829-25-4C17H18N2O6
GNE-04391241902-40-8C21H31NO3
NE 52-QQ571401728-56-0C24H28N6O
Chlorhexidine dihydrochloride;Chlorhexidine 2HCl;NSC-185;Chlorhexidine hydrochlorideChlorhexidindihydrochlorid3697-42-5C22H32Cl4N10
GPR40 agonist 11853982-41-8C27H30FN3O4
GSK-34848622170136-65-7C19H19N5OS
Diminazene AceturateN-Acetylglycin, Verbindung mit 4,4'-(1-Triazen-1,3-diyl)bis[benzolcarboxamidin] (2:1)908-54-3C22H29N9O6
GR 103691162408-66-4C30H35N3O3
GPR35 agonist 12079880-92-3C10H4BrN5O5
GNE-6162349371-81-7C24H23F4N5O3S
GOAT-IN-11452473-54-9C18H13ClF3NO3S
GSK-27936601613458-70-0C20H27N3O3
Copyright 2019 © ChemicalBook. All rights reserved